Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice ; volume:13 ; number:1 ; day:4 ; month:2 ; year:2011 ; pages:1-11 ; date:2.2011
Breast cancer research ; 13, Heft 1 (4.2.2011), 1-11, 2.2011
- Creator
-
Ladjemi, Maha Z.
- Contributor
-
Chardes, Thierry
Corgnac, Stéphanie
Garambois, Véronique
Morisseau, Sebastien
Robert, Bruno
Bascoul-Mollevi, Caroline
Ait Arsa, Imade
Jacot, William
Pouget, Jean-Pierre
Pèlegrin, André
Navarro-Teulon, Isabelle
SpringerLink (Online service)
- DOI
-
10.1186/bcr2826
- URN
-
urn:nbn:de:1111-2016032411433
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ladjemi, Maha Z.
- Chardes, Thierry
- Corgnac, Stéphanie
- Garambois, Véronique
- Morisseau, Sebastien
- Robert, Bruno
- Bascoul-Mollevi, Caroline
- Ait Arsa, Imade
- Jacot, William
- Pouget, Jean-Pierre
- Pèlegrin, André
- Navarro-Teulon, Isabelle
- SpringerLink (Online service)
Other Objects (12)
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
Anti‐HER2 Super Stealth Immunoliposomes for Targeted‐Chemotherapy
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
Anti‐HER2 Super Stealth Immunoliposomes for Targeted‐Chemotherapy
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells